WO2001013903A3 - Behandlung des restless leg syndroms mit einer kombination von clonidin und opioid - Google Patents

Behandlung des restless leg syndroms mit einer kombination von clonidin und opioid Download PDF

Info

Publication number
WO2001013903A3
WO2001013903A3 PCT/EP2000/007719 EP0007719W WO0113903A3 WO 2001013903 A3 WO2001013903 A3 WO 2001013903A3 EP 0007719 W EP0007719 W EP 0007719W WO 0113903 A3 WO0113903 A3 WO 0113903A3
Authority
WO
WIPO (PCT)
Prior art keywords
restless leg
leg syndrome
clonidine
opioid
treatment
Prior art date
Application number
PCT/EP2000/007719
Other languages
English (en)
French (fr)
Other versions
WO2001013903A2 (de
Inventor
Hans-Michael Brecht
Original Assignee
Boehringer Ingelheim Pharma
Hans-Michael Brecht
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR0013355-8A priority Critical patent/BR0013355A/pt
Priority to EP00956413A priority patent/EP1210076A2/de
Priority to SK245-2002A priority patent/SK2452002A3/sk
Priority to KR1020027002101A priority patent/KR20020020273A/ko
Priority to IL14764300A priority patent/IL147643A0/xx
Priority to MXPA02001295A priority patent/MXPA02001295A/es
Application filed by Boehringer Ingelheim Pharma, Hans-Michael Brecht filed Critical Boehringer Ingelheim Pharma
Priority to JP2001518041A priority patent/JP2003513014A/ja
Priority to CA002382648A priority patent/CA2382648A1/en
Priority to AU68365/00A priority patent/AU6836500A/en
Publication of WO2001013903A2 publication Critical patent/WO2001013903A2/de
Publication of WO2001013903A3 publication Critical patent/WO2001013903A3/de
Priority to NO20020792A priority patent/NO20020792D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Die Erfindung betrifft eine neue Wirkstoffkombination zur effektiveren Behandlung des Restless Leg Syndroms (RLS) bestehend aus einem α2-Agonist und einem weiteren als Monotherapie die Symptome von RLS reduzierenden Neuropsychopharmakon.
PCT/EP2000/007719 1999-08-19 2000-08-09 Behandlung des restless leg syndroms mit einer kombination von clonidin und opioid WO2001013903A2 (de)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EP00956413A EP1210076A2 (de) 1999-08-19 2000-08-09 Behandlung des restless leg syndroms mit einer kombination von clonidin und opioid
SK245-2002A SK2452002A3 (en) 1999-08-19 2000-08-09 A combination of active agents and use thereof
KR1020027002101A KR20020020273A (ko) 1999-08-19 2000-08-09 클로니딘과 아편유사약물의 배합제를 사용한 하지 불안증후군의 치료 방법
IL14764300A IL147643A0 (en) 1999-08-19 2000-08-09 Drug therapy of the restless leg syndrome
MXPA02001295A MXPA02001295A (es) 1999-08-19 2000-08-09 Tratamiento medicamentoso del sindrome de piernas inquietas.
BR0013355-8A BR0013355A (pt) 1999-08-19 2000-08-09 Tratamento com droga para a sìndrome da perna inquieta
JP2001518041A JP2003513014A (ja) 1999-08-19 2000-08-09 脚の不穏状態症候群を治療するための薬剤
CA002382648A CA2382648A1 (en) 1999-08-19 2000-08-09 Drug treatment for restless leg syndrome
AU68365/00A AU6836500A (en) 1999-08-19 2000-08-09 Drug therapy of the restless leg syndrome
NO20020792A NO20020792D0 (no) 1999-08-19 2002-02-18 Behandling av rastlöse ben syndrom med en kombinasjon av clonidin og opioid

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19938823A DE19938823A1 (de) 1999-08-19 1999-08-19 Medikamentöse Behandlung des Restless Leg Syndroms
DE19938823.7 1999-08-19

Publications (2)

Publication Number Publication Date
WO2001013903A2 WO2001013903A2 (de) 2001-03-01
WO2001013903A3 true WO2001013903A3 (de) 2001-08-23

Family

ID=7918572

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/007719 WO2001013903A2 (de) 1999-08-19 2000-08-09 Behandlung des restless leg syndroms mit einer kombination von clonidin und opioid

Country Status (21)

Country Link
US (1) US20010053777A1 (de)
EP (1) EP1210076A2 (de)
JP (1) JP2003513014A (de)
KR (1) KR20020020273A (de)
CN (1) CN1368878A (de)
AR (1) AR025329A1 (de)
AU (1) AU6836500A (de)
BR (1) BR0013355A (de)
CA (1) CA2382648A1 (de)
CO (1) CO5190708A1 (de)
CZ (1) CZ2002516A3 (de)
DE (1) DE19938823A1 (de)
IL (1) IL147643A0 (de)
MX (1) MXPA02001295A (de)
NO (1) NO20020792D0 (de)
PE (1) PE20010738A1 (de)
PL (1) PL364871A1 (de)
SK (1) SK2452002A3 (de)
TR (1) TR200200450T2 (de)
UY (1) UY26296A1 (de)
WO (1) WO2001013903A2 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE323491T1 (de) 1997-12-22 2006-05-15 Euro Celtique Sa Peroral zu verabreichende arzneiform enthaltend eine kombination von einem opioid agonisten und naltrexon
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
ES2253370T3 (es) 2000-04-21 2006-06-01 PHARMACIA & UPJOHN COMPANY LLC Cabergolina para el tratamiento del sindrome de fibromialgia y de fatiga cronica.
BR0110188A (pt) * 2000-04-21 2003-03-05 Upjohn Co Compostos selecionados para o tratamento de sìndromes de fibromialgia e de fadiga crÈnica
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10066158B4 (de) * 2000-08-24 2007-08-09 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung des Restless-Legs-Syndroms
DE10041479A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
US20070243240A9 (en) * 2000-08-24 2007-10-18 Fred Windt-Hanke Transdermal therapeutic system
AR031152A1 (es) 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
ES2319265T3 (es) * 2001-03-30 2009-05-06 Toray Industries, Inc. Farmacos para el sindrome de piernas inquietas.
WO2002083141A1 (en) * 2001-04-17 2002-10-24 Pharmacia & Upjohn Company Treatment of fibromyalgia and chronic fatigue syndrome
ATE493130T1 (de) 2001-05-11 2011-01-15 Endo Pharmaceuticals Inc Opioid enthaltende arzneiform gegen missbrauch
US20030073609A1 (en) * 2001-06-29 2003-04-17 Pinkerton Thomas C. Enhanced pharmacokinetic profile of intradermally delivered substances
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US20060263419A1 (en) * 2002-03-12 2006-11-23 Hans-Michael Wolff Transdermal therapeutic system for Parkinson's Disease
ES2627298T3 (es) * 2002-04-05 2017-07-27 Mundipharma Pharmaceuticals S.L. Preparación farmacéutica que contiene oxicodona y naloxona
DE10220230A1 (de) * 2002-05-06 2003-11-27 Sanol Arznei Schwarz Gmbh Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms
AU2003257418A1 (en) * 2002-06-19 2004-01-06 Solvay Pharmaceuticals Gmbh Medicament for the treatment of diseases requiring inhibition or a reduction in the activity of ph value-regulating bicarbonate transporter proteins
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
ES2239196T3 (es) 2002-12-02 2005-09-16 Schwarz Pharma Ag Suministro iontoforetico de rotigotina para el tratamiento de la enfermedad de parkinson.
DE10338174A1 (de) * 2003-08-20 2005-03-24 Lts Lohmann Therapie-Systeme Ag Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit
EP1604666A1 (de) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
EP1604667A1 (de) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung des Restless Leg Syndroms
AP2274A (en) * 2005-01-28 2011-08-19 Euro Celtiques Sa Alcohol resistant dosage forms.
EP1695700A1 (de) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Darreichungsform enthaltend Oxycodon und Naloxon
EP1702558A1 (de) 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
EP1813276A1 (de) * 2006-01-27 2007-08-01 Euro-Celtique S.A. Manipulationssichere Dosierformen
EP2007369A4 (de) 2006-04-03 2009-07-01 Teva Pharma Verwendung von rasagilin zur behandlung des syndroms der ruhelosen beine
WO2008079727A2 (en) * 2006-12-22 2008-07-03 Allergan, Inc. Compositions comprising an pan-alpha-2 receptor agonist and an anticonvulsant for treating chronic pain
EP2309993A1 (de) * 2008-06-25 2011-04-20 US Worldmeds LLC Hautpflaster und lofexidin enthaltende formulierungen mit verzögerter freisetzung zur transdermalen und oralen verabreichung
KR20110133602A (ko) 2009-03-10 2011-12-13 유로-셀티큐 에스.에이. 옥시코돈 및 날록손을 포함하는 즉시 방출 제약 조성물
US20180264013A1 (en) * 2010-07-08 2018-09-20 Wellesley Pharmaceuticals, Llc Composition and methods for treating sleep disorders
KR20150017763A (ko) * 2012-06-11 2015-02-17 싸이코제닉스 아이엔씨. 파킨슨병 치료와 관련된 운동 장애 부작용의 치료
JP2016525138A (ja) 2013-07-23 2016-08-22 ユーロ−セルティーク エス．エイ． 疼痛および腸内ディスバイオシスをもたらす疾患および／または腸内細菌移行に対するリスクを高める疾患に罹患している患者における痛みの治療への使用のためのオキシコドンおよびナロキソンの組み合わせ
CA2924236C (en) 2013-10-07 2020-01-07 Teikoku Pharma Usa, Inc. Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine
KR101827980B1 (ko) 2013-10-07 2018-02-13 테이코쿠 팔마 유에스에이, 인코포레이티드 덱스메데토미딘 경피 전달 장치 및 이의 사용 방법
ES2856189T3 (es) 2013-10-07 2021-09-27 Teikoku Pharma Usa Inc Métodos y composiciones para el tratamiento del trastorno de hiperactividad por déficit de atención, ansiedad e insomnio utilizando composiciones transdérmicas de dexmedetomidina
WO2018052926A1 (en) * 2016-09-13 2018-03-22 Mindlab LLC Medicine combinations and treatment of restless leg syndrome
PT3906927T (pt) * 2020-05-04 2022-07-27 Bioprojet Pharma Utilização de agonistas parciais da dopamina d3 para o tratamento de distúrbios do sistema nervoso central
CN115154448B (zh) * 2022-08-04 2024-01-30 谭竞 一种治疗不宁腿综合征的药物及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0256798A1 (de) * 1986-08-13 1988-02-24 Anaquest, Inc. Anästhesierende Zusammensetzung
WO1999024023A2 (de) * 1997-11-11 1999-05-20 Grünenthal GmbH FORMULIERUNG EINER KOMBINATION AUS OPIOID UND α-ADRENERGEM AGONISTEN UND DEREN VERWENDUNG
WO2000025821A1 (en) * 1998-11-04 2000-05-11 Jan Hedner Method of treating and diagnosing restless legs syndrome and corresponding means
WO2000054773A1 (en) * 1999-03-12 2000-09-21 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0256798A1 (de) * 1986-08-13 1988-02-24 Anaquest, Inc. Anästhesierende Zusammensetzung
WO1999024023A2 (de) * 1997-11-11 1999-05-20 Grünenthal GmbH FORMULIERUNG EINER KOMBINATION AUS OPIOID UND α-ADRENERGEM AGONISTEN UND DEREN VERWENDUNG
WO2000025821A1 (en) * 1998-11-04 2000-05-11 Jan Hedner Method of treating and diagnosing restless legs syndrome and corresponding means
WO2000054773A1 (en) * 1999-03-12 2000-09-21 Nitromed, Inc. Dopamine agonists in combination with nitric oxide donors, compositions and methods of use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BAILEY R. ET AL: "Chronic L-DOPA treatment of mice: a behavioural and biochemical study", J NEURAL TRANSMISSION, vol. 50, 1981, pages 209 - 224, XP000989770 *
COLLADO-SEIDEL V. ET AL: "Aetiology and treatment of restless legs syndrome.", CNS DRUGS, (1999) 12/1 (9-20)., XP000989833 *
SCHENK C. H. ET AL: "Parasomnias. Managing bizarre sleep related behavior disorders", POSTGRADUATE MEDICINE, vol. 107, no. 3, March 2000 (2000-03-01), XP000989817 *
ZOE A. ET AL: "High-dose clonidine in a case of restless legs syndrome.", ANNALS OF PHARMACOTHERAPY, (1994) 28/7-8 (878-881)., XP000989816 *

Also Published As

Publication number Publication date
CZ2002516A3 (cs) 2002-05-15
SK2452002A3 (en) 2002-06-04
CO5190708A1 (es) 2002-08-29
DE19938823A1 (de) 2001-02-22
MXPA02001295A (es) 2002-08-12
IL147643A0 (en) 2002-08-14
AU6836500A (en) 2001-03-19
PL364871A1 (en) 2004-12-27
AR025329A1 (es) 2002-11-20
UY26296A1 (es) 2001-04-30
CN1368878A (zh) 2002-09-11
PE20010738A1 (es) 2001-07-16
WO2001013903A2 (de) 2001-03-01
NO20020792L (no) 2002-02-18
BR0013355A (pt) 2002-04-30
CA2382648A1 (en) 2001-03-01
NO20020792D0 (no) 2002-02-18
TR200200450T2 (tr) 2002-08-21
KR20020020273A (ko) 2002-03-14
JP2003513014A (ja) 2003-04-08
EP1210076A2 (de) 2002-06-05
US20010053777A1 (en) 2001-12-20

Similar Documents

Publication Publication Date Title
WO2001013903A3 (de) Behandlung des restless leg syndroms mit einer kombination von clonidin und opioid
WO1999048484A3 (en) Use of cabergoline in the treatment of restless legs syndrome
MXPA05006790A (es) Usos de antagonistas del receptor adenosina a2a.
EG23228A (en) Active compound combinations having insecticidal and acaricidal properties.
LT2000095A (en) Aerosolised active agent delivery
PL398491A1 (pl) Diazabicykliczny związek (cis)-3-(5,6-dichloro-3-pirydynylo)-3,6-diazabicyklo[3,2,0]-heptan, środek do leczenia i ich zastosowanie
WO2002036123A3 (en) New treatments for restless legs syndrome
HK1043064A1 (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
HK1049284A1 (en) Benzimidazole compounds having nociceptin receptoraffinity
IL158867A0 (en) Ostepontin and agonists thereof in treatment and/or prevention of neurological diseases
MXPA03004459A (es) Inhibidores de imidazol y benzimidazol caspasa y usos de los mismos.
ZA200200106B (en) Orally active androgens.
WO2001013902A3 (de) Wirkstoffkombination enthaltend Clonidin und Pramipexol
EP1453525A4 (de) Selektives targeting von apoptotischen zellen
ZA200110127B (en) Substituted benzimidazole.
ZA978638B (en) Antimycotic agents having high active compound release.
AU1586202A (en) Active noise compensation
HK1033876A1 (en) Use of nmda antagonists for treatment of irritablebowel syndrome.
GB2378690B (en) Active noise cancellation arrangement with heat dissipation
HUP0104820A3 (en) Substituted benzimidazoles, production and use thereof as agents for combating parasitic protozoas
MXPA03000650A (es) Compuesto farmaceuticamente activo.
ITTO980718A0 (it) Corpo portante per dispositivi tensionatori, in particoalre di cinghie di trasmissione.
WO2003072047A3 (en) Idothyronine compositions
RU2000104127A (ru) Штамм bacillus subtilis x-15, используемый для профилактики и лечения эндометритов у коров
WO2002007766A8 (en) Use of d5-dopamine receptor agonists in the manufacture of a medicament for the treatment of dyskinesia

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AU BG BR CA CN CZ EE HR HU ID IL IN JP KR LT LV MX NO NZ PL RO SG SI SK TR UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 147643

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2000956413

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/00095/MU

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2000 106381

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/001295

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 008115559

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: PV2002-516

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: P20020145A

Country of ref document: HR

Ref document number: P-102/02

Country of ref document: YU

WWE Wipo information: entry into national phase

Ref document number: 2382648

Country of ref document: CA

Ref document number: 1020027002101

Country of ref document: KR

Ref document number: 2452002

Country of ref document: SK

Ref document number: 2002/00450

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 200200203

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 517617

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 68365/00

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1020027002101

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 20020182

Country of ref document: UZ

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: PV2002-516

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 2000956413

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000956413

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV2002-516

Country of ref document: CZ